Cargando…
Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients
BACKGROUND: This study aims to better define prognostic factors for patients with metastatic urothelial carcinoma (mUC), and to identify patients who will benefit from first-line cisplatin-based chemotherapy. We test the hypothesis that early objective response (EOR), defined as the occurrence of an...
Autores principales: | Roubaud, Guilhem, Brouste, Véronique, Beuzeboc, Phillipe, Fléchon, Aude, Tosi, Diego, Lavau-Denes, Sandrine, Chevreau, Christine, Culine, Stéphane, Oudard, Stéphane, Quivy, Amandine, Pourquier, Philippe, Houédé, Nadine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641378/ https://www.ncbi.nlm.nih.gov/pubmed/26555878 http://dx.doi.org/10.1186/s12952-015-0037-5 |
Ejemplares similares
-
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France
por: Houédé, Nadine, et al.
Publicado: (2015) -
Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study
por: Orré, Mathieu, et al.
Publicado: (2017) -
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
por: Pulido, Marina, et al.
Publicado: (2018) -
How to improve adherence of guidelines for localized testicular cancer surveillance: A Delphi consensus study
por: Da Silva, Angélique, et al.
Publicado: (2022) -
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
por: Culine, Stéphane, et al.
Publicado: (2023)